Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis

Andrew Blauvelt, Tsen‐Fang Tsai, Richard G. Langley, Megan Miller, Yaung‐Kaung Shen, Yin You, Ya‐Wen Yang, Kim Papp, L. Puig